Biotech Aims to Slim Fat Without Slashing Muscle
A wave of weight-loss drugs seeks to burn fat while preserving or boosting lean muscle, addressing the muscle loss seen with current GLP-1 therapies. Beyond reusing older drugs like bimagrumab, new combos (e.g., CagriSema) and Cambrian Biotech’s ATX-304 show early promise in raising metabolic rate and cutting visceral fat, though findings are preliminary and regulatory or payer hurdles remain. If proven, these approaches could enable body recomposition across broader age groups.